Latest news with #ZYUS
Yahoo
22-05-2025
- Business
- Yahoo
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Paving the way for evidence-based solutions in cancer pain management with its lead drug product, Trichomylin® softgel capsules SASKATOON, Saskatchewan, May 22, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms. While researchers highlight the need for further research to assess the full therapeutic potential of cannabinoids, the findings signal a critical shift in the scientific conversation. This emerging body of evidence reinforces the importance of rigorous clinical research, product purity and consistency, and reinforces ZYUS' commitment to advancing evidence-based cannabinoid therapies. "As we finalize site initiation for UTOPIA-1, we are proud to advance clinical development of Trichomylin® softgel capsules," said Brent Zettl, President and CEO of ZYUS. "Our research aims to bridge the gap between conventional treatments like opioids and NSAIDs, and deliver an alternative, evidence-based pharmaceutical option for cancer pain. This trial is a pivotal step in our journey to improve patient outcomes and quality of life." About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2, begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2 begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025 are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts For more information, please contact: ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@
National Post
22-05-2025
- Health
- National Post
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Article content Article content SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the 'Company') (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. Article content The Phase 2 UTOPIA clinical trial will consist of Phase 2A ('UTOPIA-1') and Phase 2B ('UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin ® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Article content Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. Article content ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a 'strong consensus' supporting cannabinoids for managing cancer-related symptoms. While researchers highlight the need for further research to assess the full therapeutic potential of cannabinoids, the findings signal a critical shift in the scientific conversation. This emerging body of evidence reinforces the importance of rigorous clinical research, product purity and consistency, and reinforces ZYUS' commitment to advancing evidence-based cannabinoid therapies. Article content 'As we finalize site initiation for UTOPIA-1, we are proud to advance clinical development of Trichomylin ® softgel capsules,' said Brent Zettl, President and CEO of ZYUS. 'Our research aims to bridge the gap between conventional treatments like opioids and NSAIDs, and deliver an alternative, evidence-based pharmaceutical option for cancer pain. This trial is a pivotal step in our journey to improve patient outcomes and quality of life.' Article content ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Article content This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2, begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans', 'will' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2 begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025 are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact: Article content ZYUS Media Inquiries media@ 1-833-651-7723 Article content Article content Article content
Business Wire
16-05-2025
- Business
- Business Wire
ZYUS Life Sciences Announces Closing of Unit Offering
SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the ' Company ') (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press releases dated May 1 and May 6, 2025, it has closed the second and final tranche (the ' Second Tranche ') of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") through the issuance of a further 871,212 Units for gross proceeds of $574,999.92. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on May 6, 2025) (the ' First Tranche ') is approximately $1.37 million. The Company issued a total of 2,083,333 Units each priced at $0.66 per Unit in the Offering. Each Unit consists of one common share of the Company (a " Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a ' Warrant '), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the " TSXV"). The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance and use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans', 'will' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, the Company's ability to obtain TSXV final acceptance and use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
National Post
07-05-2025
- Business
- National Post
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
Article content Article content SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the ' Company ') (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed a first tranche (the ' First Tranche ') of its non-brokered private placement (the ' Offering ') of units of the Company (each a ' Unit ') previously announced on May 1, 2025 for up to $2,000,000. Under the First Tranche of the Offering 1,212,121 Units were issued at a price of $0.66 per Unit for gross proceeds of approximately $800,000.000. The Company expects to close an additional tranche shortly. Article content Each Unit is priced at $0.66 and consists of one common share of the Company (a ' Common Share ') and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a ' Warrant '), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. Article content The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the ' TSXV '). The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. Article content The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ' U.S. Securities Act '), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. Article content ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X (formerly known as Twitter) @ZYUSCorp. Article content This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, close of the balance of the Offering and use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans', 'will' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, close the balance of the Offering and use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Yahoo
07-05-2025
- Business
- Yahoo
ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, May 07, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed a first tranche (the "First Tranche") of its non-brokered private placement (the "Offering") of units of the Company (each a "Unit") previously announced on May 1, 2025 for up to $2,000,000. Under the First Tranche of the Offering 1,212,121 Units were issued at a price of $0.66 per Unit for gross proceeds of approximately $800,000.000. The Company expects to close an additional tranche shortly. Each Unit is priced at $0.66 and consists of one common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV"). The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X (formerly known as Twitter) @ZYUSCorp.
